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Abstract: Four 4-hydroxycoumarin derivatives were synthesized and the structure was confirmed by NMR spectroscopy and Mass spectrometry. 
Tested compounds have shown significant antimicrobial activity against Bacillus subtilis subsp. spizizenii, Bacillus cereus, Staphylococcus aureus, 
and Staphylococcus epidermidis, and the effect of more halogens on the benzene nucleus, as well as the combination of halogen and alkyl 
groups, on the antimicrobial activity, was investigated.  
According to the docking study, these compounds can operate simultaneously on two enzymes, amylase and gyrase (1BAG and 1KZN), which 
are known to play an important role in bacterial life. Obtained docking study parameters for tested compounds showed an association with the 
in vitro results of the antimicrobial activity of these compounds. In silico tests of molecular properties of the tested compounds showed that 
the compounds met Lipinski's rule of five. In this paper, the ADME parameters of tested compounds were also calculated: Caco2 (in vitro Caco2 
cell permeability), HIA (human intestinal absorption), MDCK (in vitro Mandin Darby Canine Kidney (MDCK) cell permeability), TPSA (topological 
polar surface area), etc. 
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INTRODUCTION 
NE of the reasons that drive researchers to 
synthesize new substances is the resistance of 
microbes to applied antibiotics. Since the last century, 
there has been a big interest in coumarin substances, 
particularly in the synthesis of their derivatives with 
antimicrobial activity.[1,2] Antibacterial drugs that target 
only one enzyme often lead to bacterial resistance due to 
single-mutation. Drugs that can operate in multiple 
locations within the same enzyme or simultaneously act on 
several enzymes that are important for the metabolism of 
essential microorganisms reduce the ability of bacteria to 
develop resistance.[3] 
 In a rational design of new biologically active 
compounds, various synthetic methods have been used to 
connect two or more biologically active molecules into a 
new structure with improved activity compared to the 
initial molecules. The presence of coumarin moiety has an 
important pharmacological and therapeutic role due to 
anti-inflammatory, anticoagulant, anticancer, antimicrobic, 
and antineurodegenerative properties, therefore the 
scientific interest in these compounds is enormous. 
Numerous coumarin derivatives with biological activity 
have been synthesized.[4–8] On the other side, cinnamic 
acids are a group of aromatic carboxylic acids (C6–C3) 
appearing naturally in the plant kingdom.[9] Cinnamic acids 
are formed in the biosynthetic pathway leading to 
O 
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phenylpropanoids, coumarins, lignans, isoflavonoids, 
flavonoids, stilbenes, aurones, anthocyanins, spermidines, 
and tannins.[10] In the last ten years, the interest of 
researchers on the cinnamic acid moiety has notably 
increased. Several reviews and studies have appeared in 
the literature focusing on a different medicinal application 
of cinnamic-related molecules, for example, antimicrobial 
activity.[11,12] Some coumarin derivatives contain both 
components: coumarin and cinnamic.[13–15] 
 The inhibition of bacterial enzymes is a well-known 
mechanism by which drugs induce antibacterial activity. 
DNA gyrase is a bacterial protein from the topoisomerase 
family, which is involved in DNA transcription and 
replication processes. Escherichia coli DNA gyrase is a type 
of topoisomerase II that introduces negative supercoils by 
utilizing the free energy generated by ATP hydrolysis. This 
step is essential for DNA transcription and translation 
processes, so gyrase is a suitable target for antibacterial 
agents. Several classes of antibiotics have been used as 
inhibitors of gyrase activity for years. Some of them show high 
efficacy: quinolones (norfloxacin), coumarins (novobiocin and 
clorobiocin), and cyclothialidines.[16]  
 Quinolones interact with subunit A of DNA gyrase, 
whereas cyclothialidins and coumarins interact with the B 
subunit of this enzyme. Clorobiocin and novobiocin are the 
most important members of the coumarin family. These 
drugs are natural compounds that inhibit gyrase activity by 
competitively binding to the ATP binding site. The coumarin 
binding site completely overlaps with the ATP binding site 
as previously shown on the crystal structures of the 24 kDa 
gyrase domain inhibitory complexes. It has been shown 
that binding properties of coumarin ligands to the 24 kDa 
fragment are quite similar to those of the B subunit. 
Because both classes of antibiotics have limitations and 
side effects, the search for new gyrase inhibitors remains of 
great importance. Numerous synthetic coumarins with 
limited side effects have been designed. In recent years, 
there have been numerous attempts to generate small 
molecules that exhibit better or novobiocin-like inhibitory 
activity. The crystal structure of the clorobiocin-24 kDa 
gyrase complex was published and the coordinates were 
stored in a protein database (Protein Data Bank, PDB). 
Gyrase is present in prokaryotes and some eukaryotes, but 
not present in humans. This fact makes gyrase a good target 
for antibiotics.[17] Alpha-amylase from Bacillus subtilis 
complexed with maltopentose (PDB ID: 1BAG) has been 
described as a target in docking studies.[18] Activation of the 
alpha-amylase receptor from Bacillus subtilis building a 
complex with maltopentose (1BAG) is associated with 
antibacterial activity. Based on this, the 1BAG receptor was 
selected as the biological target for the docking of the 
synthesized compounds. A correlation between microbial  
activity in vitro and the binding energy results of the 
docking study has been established. It has been shown that 
blocking this receptor leads to antibacterial activity. 
Binding of a ligand to an active site that is composed of 18 
amino acids provides the best answer.[19,20] 
 4-Hydroxycoumarin derivatives showed good micro-
biological activity and interesting physicochemical proper-
ties in our previous studies.[14,15,21] We proved that the 
presence of halogen on the benzene nucleus of these com-
pounds increases the activity. In this paper, we have gone 
a step further. We wanted to examine the effect of more 
halogens on the benzene nucleus, as well as the combina-
tion of halogen and alkyl groups on microbiological activity. 
Also, this study aims were to evaluate the affinity of the 
binding of selected synthesized 4-hydroxycoumarin deriva-
tives (which contain in their structure coumarin and cinnamic 
acid residues) to bacterial enzymes gyrase and amylase and 
to correlate obtained parameters in silico with obtained 
results of in vitro antimicrobial activity of compounds. 
 Docking does not answer all the questions which are 
important in the initial stages of testing for biologically 
active compounds, so data about cell membrane 
permeability are also valuable. Therefore, in this paper, the 
next parameters were also calculated: Caco2 (in vitro Caco2 
cell permeability), HIA (human intestinal absorption), 
MDCK (in vitro Mandin Darby Canine Kidney (MDCK) cell 
permeability), TPSA (topological polar surface area), etc. 
 
EXPERIMENTAL 
Materials and Methods 
 
TESTED COMPOUNDS 
All derivatives used in the test were synthesized at the 
Department of Pharmaceutical Chemistry, Faculty of 
Pharmacy, University of Sarajevo, according to the 
previously published method.[21] For four synthesized 
derivatives structure was confirmed by NMR spectroscopy 
and mass spectrometry. 
 
DETERMINATION OF MELTING POINT 
Melting points of tested compounds were determined by 
DSC (Differential Scanning Calorimetry) thermal analysis on 
the device Diamond DSC (Perkin Elmer). 
 
NMR SPECTROSCOPY 
The spectra were recorded on Bruker AV600 NMR 
spectrometer, operating frequencies for 1H and 13C NMR 
were 600.130 MHz and 150.903 MHz, respectively. Samples 
were dissolved in 0.6 mL of deuterated dimethyl sulfoxide 
(DMSO-d6). The scale for 1H is calibrated according to the 
signal shift of tetramethylsilane (TMS) and for 13C according 
to the signal shift of DMSO-d6. 
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MASS SPECTROMETRY 
The analysis was performed on an Agilent 7890A GC 
apparatus equipped with 5975 C MSD. An HP-5MSI capillary 
column (Agilent Technologies, 0.25 mm diameter, 30 m 
long, 0.25 μm film thickness) was used. Samples were 
injected in split mode, in a volume of 1 μL. The carrier gas 
(He) flow rate was 2.1 mL/min at 60 °C (at constant 
pressure). The temperature of the column is programmed 
linearly in the range of 60–315 °C with a temperature 
increase of 25 °C min–1. The mass spectra were obtained in 
electron ionization mode (EI) with ionic energy of 70 eV. 
The scanning range was m / z 33–550. The identification of 
the compounds is based on the interpretation of ionic 
fragmentation. The ion source temperature was 230 °C and 
the quadrupole temperature was 150 °C. 
 
ANTIMICROBIAL ACTIVITY OF TESTED COMPOUNDS BY 
DIFFUSION METHOD 
Antimicrobial activity was tested on standard strains of 
microorganisms: 
• Bacillus subtilis subsp. spizizenii ATCC 6633 
• Bacillus cereus ATCC 11778 
• Staphylococcus aureus ATCC 6538P  
• Staphylococcus epidermidis ATCC 12228. 
Tablets used as reference standards:  
• gentamicin 30 µg; 
• erythromycin 15 µg. 
 
THE DIFFUSION METHOD PROCEDURE 
The European Pharmacopoeia method of diffusion is based 
on a comparison of the diameter of the zones of inhibition 
of the test sample solutions with the zones given by the 
standards. One mg of the compound was dissolved in 1 mL 
of DMSO. The solution thus prepared was used for further 
testing. Müller-Hinton agar and nutrients A, B, E, and F 
were used for the determination of antimicrobial activity by 
diffusion method. 
 Holes 6–9 mm in diameter are made in a solid 
nutrient medium. The holes were made using a stainless 
steel drill pipe 10 cm high and 6 mm ± 0.1 mm in diameter. 
Before use, the tubes were sterilized by heating to 150 °C 
and cooled. The drilled holes were filled with test 
compounds and a 100 μL blank (solvent), as well as tablets 
with standard compounds. Prepared plates were left at 
room temperature (or 4 °C) for 1 to 4 hours to diffuse the 
test sample into the inoculated medium. 
 Plates were then transferred to a thermostat, where 
bacterial strains were incubated for 18 hours at 37 °C. Upon 
completion of incubation, with an accuracy of 0.1 mm, the 
zones of inhibition formed by the action of the test com-
pounds were read. The susceptibility of the microorganisms 
to the test compounds was measured by the width of the 
inhibition zone and compared to the inhibition zone of the 
chemotherapeutic agent that served as the standard. In the 
case of the insensitivity of the microorganism to the test 
compound, the microbes grow along the edge of the sam-
ple hole, so there is no zone of growth inhibition. The inhi-
bition zones of the tested compounds were measured on a 
Readbiotic device. The measurement was done by placing 
a plate on the flat plate of the device and moving the part 
of the device representing the ruler to read the zones of 
inhibition in millimeters. 
 
DOCKING STUDIES AND AFFINITY ASSESSMENT FOR THE 
RECEPTOR 
AutoDockTools (ADT) was used to prepare, perform, and 
analyze docking simulations. The Lamarckian Genetic 
Algorithm (LGA) was applied to search for the most energy-
efficient conformers. During docking simulations, a 
maximum of 100 conformers of each compound was 
analyzed. The structures of the tested compounds were 
optimized in Chem3D Ultra 9.0.1. program using the AM1 
semi-empirical quantum-chemical method. Docking 
studies were performed using AutoDock 4.0. program. 
Discovery Studio Visualizer software was used to prepare 
receptors and ligands. PyMol 1.1 software was used to 
finally visualize the best conformation (test compound-
receptor). The 3D coordinates of the crystallographic 
structure of the receptor were taken from the Brookhaven 
protein data bank (www.pdb.org) under the characteristic 
PDB code for each receptor. For docking studies for 
antibacterial activity, topoisomerase II DNA gyrase enzyme 
whose 3D coordinates are in the protein database (PDB ID: 
1KZN) and alpha-amylase from Bacillus subtilis complexed 
with maltopentose (PDB ID: 1BAG) were used as receptors. 
Docking results are expressed through three specific 
parameters for each compound: inhibition constants (Ki), 
binding energies, and hydrogen bond formation. 
 The inhibition constant [Ki] is a parameter that 
determines what concentration of a compound is required 
to reduce the maximum rate of an enzymatic reaction by 
half.[22] The lower the value of this parameter, the higher 
the inhibitory activity. The binding energy [ΔG] is a 
parameter inversely proportional to the stability of the 
ligand-receptor complexes tested, and is calculated 
according to the equation: 
 
 ΔG = ΔH – TΔS 
 
where ΔG is binding energy, ΔH is enthalpy contribution and 
TΔS is entropy contribution. 
 When a ligand binds to a protein, the enthalpy 
decreases as a result of favoring intermolecular interactions 
and forming intermolecular bonds, while entropy increases 
as a result of the loss of the number of degrees of freedom.[23] 
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MOLECULAR PROPERTIES OF TESTED COMPOUNDS 
LogP (octanol/water partition coefficient) which is used to 
estimate lipophilicity is calculated by Molinspiration devel-
oped methodology as a sum of fragment-based contribut-
ions and correction factors (miLogP). Topological polar 
surface area (TPSA) is calculated from the surface areas that 
are occupied by oxygen and nitrogen atoms and by hydrogen 
atoms attached to them. Number of Rotatable Bonds (nRotb) 
as a measure of molecular flexibility, molecular weight (MW), 
number of hydrogen bond acceptors (nON), and hydrogen 
bond donors (nOHNH) were also calculated using online 
available software (www.molinspiration.com). 
 
ADME PARAMETERS OF TESTED COMPOUNDS 
Caco2 (in vitro Caco2 cell permeability), HIA (human intes-
tinal absorption), MDCK (in vitro MDCK cell permeability), 
BBB (in vivo blood-brain barrier penetration), PPB (in vitro 
plasma protein binding) and SKIN (in vitro skin permeabil-
ity) were calculated using online available software 
PreADMET (https://preadmet.bmdrc.kr). 
 
RESULTS AND DISCUSSION 
Chemistry 
The structures of the compounds used in the in silico and in 
vitro tests are shown in Figure 1. 
 
COMPOUND 1: 3-(3-(2,4,6-TRIMETHYLPHENYL)PROP-2-
ENOYL)-4-HYDROXY-2H-BENZOPYRAN-2-ONE 
Yield 66 %; m.p. 203.7 °C; 1H NMR (DMSO-d6) d / ppm: 2.25 
(s, 3H, H-20), 2.38 (s, 6H, H-21/H-22), 6.94 (s, 2H, H-16/H-
18), 7.34 (d, 1H, J7,8 = 8.47 Hz, H-8), 7.40 (t, 1H, J5,6 =  
7.89 Hz, J6,8 = 0.63 Hz, H-6), 7.78 (t, 1H, J7,8 = 8.47 Hz, J6,7 = 
7.41 Hz, J5,7 = 1.53 Hz, H-7), 7.92 (d, 1H, J12,13 = 16.14 Hz,  
H-13), 8.03 (d, 1H, J5,6 = 7.89 Hz, J5,7 = 1.53 Hz, H-5), 8.16 (d, 
1H, J12,13 = 16.14 Hz, H-12); 13C NMR (DMSO-d6) d / ppm: 
19.9 (C20), 20.1 (C21/C22), 100.3 (C3), 115.4 (C10), 116.2 
(C8), 124.0 (C6), 124.8 (C5), 126.4 (C13), 128.9 (C16/C18), 
130.0 (C15/C19), 135.8 (C7), 137.0 (C14), 138.7 (C17), 143.6 
(C12), 153.8 (C9), 159.0 (C2), 179.7 (C4), 191.1 (C11); MS  
m / z: 334 (M+, 5), 316 ((M-H2O) +, 100), 196 (62), 189 (13), 
162 (12), 145 (18), 130 (28), 121 (47). 
COMPOUND 2: 3-(3-(2-BROMO-4-METHYLPHENYL)PROP-
2-ENOYL)-4-HYDROXY-2H-BENZOPYRAN-2-ONE 
Yield 72 %; m.p. 209.2 °C; 1H NMR (DMSO-d6) d / ppm: 2.32 
(s, 3H, H-20), 7.26 (d, 1H,  J = 7.95 Hz, H-16), 7.32 (d, 1H, J = 
8.43 Hz, H-8), 7.37 (t, 1H, J = 7.37 Hz, H-6), 7.51 (s, 1H, 
 H-18), 7.67 (d, 1H, J = 7.95 Hz, H-15), 7.76 (t, 1H, J =  
8.43, 7.37, 1.56 Hz, H-7), 7.98 (d, 1H, J = 7.89, 1.56 Hz, H-5), 
8.16 (d, 2H, J=15,69 Hz, H-12/H-13); 13C NMR (DMSO-d6)  
d / ppm: 19.8 (C21), 100.5 (C3), 115.2 (C10), 116.1 (C8), 
124.0 (C12), 124.0 (C6), 124.7 (C5), 124.9 (C19), 127.7 
(C15), 128.6 (C16), 130.5 (C14), 133.1 (C18), 135.9 (C7), 
142.6 (C13), 142.9 (C17), 153.7 (C9), 158.8 (C2), 179.5 (C4), 
190.6 (C11); MS m / z: 386 (M+, 4), 305 ((M-Br)+, 100), 215 
(8), 185 (17), 115 (19). 
 
COMPOUND 3: 3-(3-(2-FLUORO-6-CHLOROPHENYL)PROP-
2-ENOYL)-4-HYDROXY-2H-BENZOPYRAN- 2-ONE 
Yield 62 %; m.p. 194.1 °C; 1H NMR (DMSO-d6) d / ppm: 7.31 
(d, 1H, J = 8.58, 10.92 Hz, H-16), 7.36 (d, 1H, J = 8.40 Hz, H-
8), 7.38–7.44 (m, 2H, H-6/H-18), 7.46–7.51 (m, 1H, JC-17, F = 
9.6 Hz, H-17), 7.79 (t, 1H, J = 8.40, 1.41 Hz, H-7), 8.03 (d, 1H, 
J = 8.64, 1.41 Hz, H-5), 8.04 (d, 1H, J = 16.14 Hz, H-13), 8.45 
(d, 1H, J = 16.14 Hz, H-12); 13C NMR (DMSO-d6) d / ppm: 
100.8 (C3), 114.9 (C16), 115.1 (C10), 116.2 (C8), 124.1 (C6), 
124.8 (C5), 125.8 (C18), 127.3 (d, 3JC-14,F = 15.4 Hz, C14), 
129.4 (C12), 131.9 (d, 2JC-17,F = 9.6 Hz, C17), 133.9 (C19), 
134.0 (C13), 136.0 (C7), 153.9 (C9), 159.0 (C2), 161.8 (d, 
4JC-15,F = 249.0 Hz, C15), 179.3 (C4), 191.1 (C11); MS m / z: 
326 ((M+2-HF)+, 33), 324 ((M-HF)+, 100), 296 (49), 204 (50), 
152 (100), 113 (52), 92 (48). 
 
COMPOUND 4: 3-(3-(4-TRIFLUOROMETHYLPHENYL)PROP-
2-ENOYL)-4-HYDROXY-2H-BENZOPYRAN-2-ONE 
Yield 75 %; m.p. 180 °C; 1H NMR (DMSO-d6) d / ppm: 7.38 
(d, 1H, J7,8 = 8.32 Hz, H-8), 7.42 (t, 1H, J5,6 = 7.93 Hz, J6,8 = 
0.87 Hz, H-6), 7.77–7.81 (m, 3H, H7/H16/H18), 7.92 (d, 2H, 
J15,16 = 8.13 Hz, H15/19), 7.97 (d, J12,13 = 15.84 Hz, H-13), 
8.05 (d, 1H, J5,6 = 7.93 Hz, J5,7 = 1.62 Hz, H-5), 8.29 (d, 1H, 
J12,13 = 15.84 Hz, H-12); 13C NMR (DMSO-d6) d / ppm: 100.2 
(C3), 115.6 (C10), 116.9 (C8), 123.9 (q, JC-18,F = 272.7 Hz, 
C20), 124.8 (C6), 125.3 (C13), 125.4 (C12), 126.0 (C16/C18), 
129.5 (C15/C18), 130.6 (q, JC-17,F = 30.9 Hz, C17), 136.8 (C7), 
138.2 (C14), 143.7 (C5), 154.2 (C9), 159.5 (C2), 180.2 (C4), 
191.6 (C11); MS m / z: 360 (M+, 32), 239 (13), 215 (100), 199 
(52), 171 (38), 151 (60), 121 (100), 92 (30). 
Microbiology of Investigated 
Compounds 
Results of the antimicrobial activity of compounds 
subjected to this test by diffusion method to Gram-positive 
aerobic bacteria (Bacillus subtilis subsp. spizizenii, Bacillus 
cereus, Staphyloccocus aureus, and Staphylococcus 
epidermidis) are shown in Table 1. 
 
 
Figure 1. Structures of the tested coumarin compounds. 
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 The values of inhibition zones of tested compounds 
ranged from 8 to 24 mm. 
 Three methyl groups of compound 1 contribute to 
the lipophilicity and good activity of this compound. Com-
pounds having halogen chlorine and/or bromine, with 
zones of inhibition (ZI) of 16–23.75 mm, showed also a good 
activity. Compound 3 with fluorine and chlorine showed 
moderate activity. When the fluorine atom is directly at-
tached to the benzene nucleus, due to its electronegativity 
it destabilizes coumarin molecule and by this probably 
causes poor activity. Unlike fluorine directly attached to the 
benzene nucleus (compound 3), fluorine bound as a trifluo-
romethyl group significantly alters antibacterial activity. 
Thus, the greatest inhibition zone in the diffusion  
method was shown by the compound 3-(4-trifluoromethyl-
phenyl)prop – 2 - enoyl) – 4 – hydroxy - 2H – benzopyran – 2 - one 
(compound 4), ZI = 24.00 mm toward Bacillus cereus. A 
similar activity was shown toward Bacillus subtilis (ZI = 
23.00 mm) and slightly weaker toward Staphylococcus epi-
dermidis (ZI = 20.00 mm) and Staphylococcus aureus (ZI = 
19.00 mm). The trifluoromethyl group (CF3) is lipophilic 
which contributes to the lipophilicity and activity of the 
whole compound. 
Binding of 4-Hydroxycoumarins to 
Receptors 
The basic interaction that allows ligand binding to the 
receptor is a hydrogen bond that is established between 
the polar groups of the amino acid branches in the peptide 
chain and the polar groups on the ligand molecule. 
 Compounds that can act in multiple sites within the 
same enzyme or simultaneously act on multiple enzymes 
important for the essential metabolism of the 
microorganism reduce the ability of bacteria to develop 
resistance. In this paper, the binding of 4-hydroxycoumarin 
derivatives to two enzymes was examined: alpha-amylase 
from Bacillus subtilis (PDB ID: 1BAG) and DNA gyrase 
subunit B from Escherichia coli (PDB ID: 1KZN). 
Binding of Compounds to the  
Alpha-Amylase from Bacillus subtilis 
(PDB ID: 1BAG) 
The docking results of the selected coumarin derivatives on 
the 1BAG receptor are shown in Table 2. 
 Four 4-hydroxycoumarin derivatives were docked at 
the 1BAG receptor. 
 Compound 1 showed the binding energy of –5.17 kcal 
mol–1 and formed one hydrogen bond between the carboxyl 
group at position 2 of the coumarin ring and GLN-63. 
 Compound 2 showed the binding energy of  
–5.15 kcal mol–1 and formed one hydrogen bond. The 
carboxyl group at position 2 of the coumarin ring binds to 
the GLN-63 residue. 
 Compound 3 showed the binding energy of  
–4.63 kcal mol–1 and formed one hydrogen bond. The 
carboxyl group at position 2 of the coumarin ring binds to 
the residue of ASN-273. 
 Compound 4 exhibited the binding energy of  
–5.79 kcal mol–1 and builds two hydrogen bonds. Carboxyl 
group from the chain and the hydroxyl group at position 4 
of the coumarin ring bind to the GLN-63 residue. This is the 
only compound in the series that builds two hydrogen 
bonds over the same amino acid. 
 As for structural analogs, the logical fact is that the 
amino acids of the proteins involved in the interaction are 
often the same. Thus, in most compounds, the amino acid 
residue of GLN-63 forms hydrogen bonds with the polar 
moieties of the compound molecules (compounds 1, 2, 4). 
Polar parts of the molecules of the test compounds that 
build hydrogen bonds with the amino acid residues at 
docking with 1BAG are carboxyl group at position 2 of the 
coumarin ring, hydroxyl group at position 4 of the coumarin 
ring, oxygen from the coumarin nucleus at position 1 and 
carboxyl group from the chain.  
 Lower binding energies (the greater the negative 
number) indicate better binding of the compounds with 
bacterial amylase. Compounds with lower binding energies 
 
Table 1. Values of inhibition zones (mm) of tested 
compounds against selected bacteria (by diffusion method). 
Microorga-
nism 
Staphylococcus 
aureus 
Staphylococcus 
epidermidis 
Bacillus 
subtilis 
Bacillus 
cereus 
Compound Zone / mm 
1 22.50 18.50 21.75 23.50 
2 13.50 15.50 21.00 23.25 
3 16.00 8.00 16.00 17.75 
4 19.00 20.00 23.00 24.00 
DMSO (control)      – – – – 
Erythromycin      24.20 29.00 32.00 23.00 
Gentamicin 32.00 36.00 32.20 27.80 
 
 
Table 2. Docking results of coumarin derivatives at 1BAG: 
binding energies, inhibition constants, and amino acids 
involved in hydrogen bond formation. 
Compound 
1BAG 
Binding energy / 
kcal mol–1 
Inhibitory constant / 
µmol dm–3 
Interacting 
amino acids 
1 –5.17 162.58 GLN-63 
2 –5.15 167.71 GLN-63 
3 –4.63 403.22 ASN-273 
4 –5.79 57.45 GLN-63 
Chloramphenicol   –6.57 15.32 - 
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should also have lower inhibition constants to be consid-
ered as good enzyme inhibitors (as we can see in Table 2). 
 In docking analysis, chloramphenicol was used as the 
standard for interacting with 1BAG. The interaction of this 
drug with the receptor produced the lowest inhibition 
constant of 15.32 µmol dm–3, while the binding energy was 
–6.57 kcal mol–1. 
 Graphical simulations of binding of compounds 1–4 
to receptor 1BAG are shown in Figure 2. 
 A comparison of the results obtained with docking 
with the results of antibacterial activity in vitro shows a rel-
atively good concurrence. 
 Compound 4 (CF3 group as a substituent) which 
showed the best in vitro activity on Bacillus subtilis, also 
showed almost the lowest binding energy (–5.79 kcal mol–1) 
at 1BAG. This is the only compound in the series that builds 
over the same amino acid two hydrogen bonds. Also,  
this compound showed a low inhibition constant  
(57.45 µmol dm–3). Compound 3 (F and Cl as substituents) 
showed the highest binding energy (–4.63 kcal mol–1). This 
compound also had by far the highest inhibition constant of 
403.22 µmol dm–3. In in vitro studies, this compound 
exhibited poor antibacterial activity. 
Binding of Compounds to the DNA 
Gyrase Subunit B from Escherichia coli 
(PDB ID: 1KZN) 
The docking results of selected coumarin derivatives at the 
DNA gyrase subunit B are shown in Table 3. 
 Compound 1 exhibited a binding energy of  
–4.54 kcal mol–1 and builds two hydrogen bonds. Oxygen at 
position 1 of the coumarin ring binds to the residue of ASN-
198, while hydrogen from the hydroxyl group at position 4 
of the coumarin ring binds to residue SER-199. 
 Compound 2 showed a binding energy of  
–4.72 kcal mol–1 and builds one hydrogen bond. The 
Carboxyl group at position 2 of the coumarin ring binds to 
the residue of HIS-116. 
 Compound 3 showed a binding energy of  
–4.30 kcal mol–1 and does not form hydrogen bonds. Oxy-
gen at position 1 of the coumarin ring forms hydrophobic 
interactions with the amino acid ASN-198. 
 Compound 4 showed a binding energy of  
–4.52 kcal mol–1and builds one hydrogen bond. The carboxyl 
group in the chain binds to residue ASN-198. 
 As for structural analogs, the logical fact is that the 
amino acids of the proteins involved in the interaction are 
often the same. Thus, the amino acid residues of ASN-198 
form hydrogen bonds with the polar moieties of the com-
pounds 1 and 4. 
 Polar moieties of the molecules of the test com-
pounds that form hydrogen bonds with the residues of the 
amino acids of the DNA gyrase receptor are carboxyl group 
at position 2 of the coumarin ring, the hydroxyl group at 
position 4 of the coumarin ring, the oxygen from the cou-
marin nucleus at position 1, and the carboxyl group from 
the chain. Compounds with lower binding energies should 
also have lower inhibition constants (as we see in Table 3). 
 In docking analysis, clorobiocin was used as the 
standard for interacting with 1KZN. The interaction of this 
drug with the receptor resulted in an inhibition constant  
of 486.72 µmol dm–3, while the binding energy was  
–4.52 kcal mol–1. 
 Graphical simulations of the binding of compounds 
1–4 to 1KZN receptor are shown in Figure 3. 
 The high binding energy was shown by compound 3 (F 
and Cl as substituents). This compound also had by far the 
highest inhibition constant of 704.12 µmol dm–3. In in vitro 
studies, this compound showed poor antibacterial activity. 
Predicting the Permeability of 
Derivatives Through Membranes 
Unfortunately, docking, as a powerful and highly 
sophisticated method, does not answer the many 
questions that arise in the initial stages of testing for 
 
Figure 2. Binding mode of compounds 1 (a), 2 (b), 3 (c) and 
4 (d) to receptor 1BAG. 
 
Table 3. Docking results of coumarin derivatives at 1BAG: 
binding energies, inhibition constants, and amino acids 
involved in hydrogen bond formation. 
Compound 
1BAG 
Binding energy / 
kcal mol–1 
Inhibitory constant / 
µmol dm–3 
Amino acids in 
hydrogen bonds 
1 –4.54 471.77 ASN-198, 
SER-199 
2 –4.72 345.92 HIS-116 
3 –4.30 704.12 – 
4 –4.52 483.12 ASN-198 
Clorobiocin –4.52 486.72 – 
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biologically active compounds. Numerous other 
parameters provide information about the potency of 
some compounds to become drugs. The ability of the drug 
to pass through the membrane is one of the first 
parameters tested in the modeling of the new drugs. 
Lipinski's rule of five is well known.[24] According to Lipinski, 
a molecule will be able to pass the membrane by passive 
intestinal diffusion if it has: molecular weight of less than 
500 g mol–1, a logP value of less than 5 representing its 
hydrophobicity, no more than 5 hydrogen bond donors 
(HBD), and no more than 10 hydrogen bond acceptor (HBA) 
sites.[24] Further research has added two more parameters: 
topological polar surface area (TPSA) of less than or equal 
to 140 Å2 and less than 10 rotatable bonds (Rotb),[25] which 
are correlated with drug permeability and flexibility. 
 In compliance with this set of rules, a chemical 
compound would act as an orally active drug-like 
compound on the desired target. If the molecule does not 
meet any two of the above requirements, it is assumed that 
it will not be capable of absorption by passive intestinal 
diffusion. From this rule, it is evident that the lipophilicity 
of the compounds is an important parameter in the process 
of intestinal drug absorption. But based on lipophilicity, not 
only the absorption but also the distribution, elimination, 
and toxicity of a drug can be predicted. 
 TPSA (Å2) is calculated as a sum of fragment 
contributions (O- and N-centered polar fragments are 
considered). Since all four synthesized compounds have the 
same number of oxygen atoms located on the coumarin 
nucleus (have the same environment), the oxygen 
contribution is the same in all four synthesized compounds, 
and the TPSA value is identical. 
 The number of Rotatable Bonds (nRotb) is a measure 
of molecular flexibility. Rotatable bond is defined as any 
single non-ring bond, bounded to nonterminal heavy (i.e., 
non-hydrogen) atom.  
 Of the four synthesized compounds, compounds 1, 
2, and 3 have the same number of rotatable bonds (3), 
while compound 4 has 4 rotatable bonds. The three 
common rotatable bonds are single bonds on a chain 
connecting the coumarin nucleus to the benzene ring while 
the fourth rotatable bond of the compound 4 is bond 
between the phenyl ring and the carbon of the CF3 group. 
The results of permeability predicting for the tested 
compounds via passive intestinal diffusion, using Lipinski's 
rule of five, are shown in Table 4. 
 All tested compounds meet the Lipinski rule of five 
(Table 4), so it is assumed that they can be absorbed by 
passive intestinal diffusion. 
 ADME parameters of tested compounds are shown 
in Table 5. 
 Permeability through monolayers of human 
intestinal epithelial cells originated from human colorectal 
carcinoma cells (Caco-2) and Madin−Darby Canine Kidney 
cells (MDCK) are widely considered to be the in vitro gold 
standard for assessing the uptake efficiency of chemicals 
into the body.[26,27] Permeability through MDCK cell lines is 
also used to estimate the effect of the blood-brain barrier 
(BBB).[28–30] Given that these tests are time- and cost-
intensive we calculated them using computer programs. 
 
Figure 3. Binding mode of compounds 1 (a), 2 (b), 3 (c) and 
4 (d) to receptor 1KZN. 
 
Table 4. Passage test of tested compounds via passive 
intestinal diffusion. 
Com-
pound TPSA / Å
2 miLogP 
MW /  
g mol–1 nON nOHNH nRotb 
1 67.51 4.55 334.37 4 1 3 
2 67.51 4.53 385.21 4 1 3 
3 67.51 4.09 344.73 4 1 3 
4 67.51 4.42 360.29 4 1 4 
TPSA - topological polar surface area; miLogP – LogP obtained by the 
Molinspiration; MW - molecular weight; nON - total number of hydrogen 
bond acceptors; nOHNH - total number of hydrogen bond donors; nRotb - 
number of rotatable bonds. 
 
Table 5. Passage test of tested compounds via passive 
intestinal diffusion. 
Compound 
Absorption 
PPB BBB SKIN MDCK 
HIA / % CaCo2 
1 95.98 16.86 91.86 0.34 –2.54 0.63 
2 96.41 22.15 100.00 0.23 –2.60 0.04 
3 96.08 22.29 100.00 0.14 –3.05 2.60 
4 95.93 20.88 95.46 0.20 –1.95 0.05 
Caco2 - in vitro Caco2 cell permeability (Human colorectal carcinoma) 
(nm/sec); HIA - Human intestinal absorption (HIA, %); BBB - in vivo blood-
brain barrier penetration (conc.brain/conc.blood); MDCK - in vitro MDCK 
cell permeability (Mandin Darby Canine Kidney) (nm/sec); PPB – Plasma 
Protein Binding (PPB) - in vitro plasma protein binding (%); SKIN – in vitro 
skin permeability (transdermal delivery) (logKp, cm hour–1) 
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 Human intestinal absorption (HIA) is one of the most 
important ADME properties and also one of the key steps 
during the drugs’ transporting to their targets.[31] "Poor" 
absorption was defined as HIA ≤ 30 %, "high" absorption as 
HIA ≥ 80 %, whereas "moderate" absorption was defined 
between these two values (30 % < HIA < 79 %). As can be 
seen from Table 5, high human intestinal absorption and in 
vitro plasma protein binding are predicted for all the syn-
thesized compounds. The prediction of plasma protein 
binding (PPB) is of paramount importance in the pharma-
cokinetics characterization of drugs, as it causes significant 
changes in the volume of distribution, clearance, and drug 
half-life. The reversible interaction between drug and 
plasma protein can also greatly influence the pharmacolog-
ical effect of the drug because only a fraction of unbound 
drug can pass across cell membranes. Thus, it can be 
expected that drugs with high protein binding tend to have 
a greater half-life compared to those with lower values. The 
greater the drug is bound to plasma protein, the less frac-
tion of free drug is there for therapeutic effect.[32] 
Determination of compounds’ blood-brain barrier permea-
bility is a prerequisite for screening compounds / bio-mole-
cules which could take effects in the central nervous 
system.[33] As can be seen from Table 5, predicted in vivo 
blood-brain penetration for all the synthesized compounds 
is poor. 
 
CONCLUSIONS 
For the four synthesized 4-hydroxycoumarin derivatives, 
the structure was confirmed using NMR spectroscopy and 
Mass spectrometry. Microbiological studies have shown 
significant activity of these compounds. The in silico param-
eters obtained in the docking study of 4-hydroxycoumarin 
derivatives at 1BAG and 1KZN receptors show concurrence 
with the results of the antimicrobial activity of these com-
pounds in vitro. According to docking, these compounds 
can operate simultaneously on two enzymes that are 
important for the metabolism of bacteria. In this way, the 
ability of bacteria to develop resistance to these com-
pounds is reduced. Additionally, Lipinski's rule of five 
showed that all tested compounds can be absorbed by pas-
sive intestinal diffusion. Having in mind all the above, deriv-
atives of this type are good candidates for further synthesis 
and research of the relationship between their structure 
and activity. 
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